Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0120 in Relapsed/Refractory Multiple Myeloma
NCT05850234Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in multiple myeloma (MM), sponsored by AstraZeneca. Started Jul 2023; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05850234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850234.